Introduction Generalized Myasthenia Gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness and fatigue. The disease is primarily mediated by pathogenic autoantibodies targeting acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) at the neuromuscular junction. These antibod